Operating Segments (Details)	3 Months Ended		9 Months Ended
	Sep. 30, 2024 USD ($)	Sep. 30, 2023 USD ($)	Sep. 30, 2024 USD ($) segment	Sep. 30, 2023 USD ($)	Dec. 31, 2023 USD ($)
Segment reporting
Number of operating segments | segment			2
Revenues		$ 130,440	$ 119,371	$ 594,547
Income (loss) from Operations	$ (1,865,236)	(1,779,056)	(5,727,002)	(5,560,069)
Amortization and Depreciation Expense	1,589	1,589	4,765	4,964
Other (Expense) Income, Net	145,855	116,354	447,792	78,037
Share-Based Compensation	56,632	65,400	174,268	229,076
Identifiable Assets	10,476,979		10,476,979		$ 9,797,326
Operating Segments [Member] | Specialized BioTherapeutics [Member]
Segment reporting
Revenues			119,371	223,870
Income (loss) from Operations	(834,654)	(705,753)	(1,978,464)	(2,227,430)
Amortization and Depreciation Expense	953	954	2,859	2,979
Other (Expense) Income, Net	1,409	1,683	(22,397)	17,696
Share-Based Compensation	20,598	27,427	62,210	82,281
Identifiable Assets	45,674		45,674		272,099
Operating Segments [Member] | Public Health Solutions [Member]
Segment reporting
Revenues		130,440		370,677
Income (loss) from Operations	(57,611)	(24,819)	(165,660)	(26,639)
Amortization and Depreciation Expense	158	159	476	496
Share-Based Compensation	618	994	1,823	2,982
Identifiable Assets	2,387		2,387		3,976
Corporate [Member]
Segment reporting
Income (loss) from Operations	(972,971)	(1,048,484)	(3,582,878)	(3,306,000)
Amortization and Depreciation Expense	478	476	1,430	1,489
Other (Expense) Income, Net	144,446	114,671	470,189	60,341
Share-Based Compensation	35,416	$ 36,979	110,235	$ 143,813
Identifiable Assets	$ 10,428,918		$ 10,428,918		$ 9,521,251